Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Nina Bhardwaj
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02334735CT.gov A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | — | Completed | — | — | — |
NCT02054104CT.gov Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | — | Terminated | — | — | — |
NCT01748747CT.gov Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery | — | Completed | — | — | — |
NCT01079741CT.gov Safety Study of Adjuvant Vaccine to Treat Melanoma Patients | — | Completed | — | — | — |
NCT01008527CT.gov Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 | — | Completed | — | — | — |
NCT00923195CT.gov Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00651703CT.gov Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients | — | Completed | — | — | — |
NCT00124124CT.gov Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine | — | Completed | — | — | — |
NCT00089063CT.gov Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma | — | Completed | — | — | — |
NCT00184067CT.gov Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma | — | Terminated | — | — | — |
Show 6 more trialsShow fewer
NCT00085189CT.gov Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | — | Completed | — | — | — |
NCT00080353CT.gov Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma | — | Completed | — | — | — |
NCT00112242CT.gov Immunotherapy of Stage III/IV Melanoma Patients | — | Completed | — | — | — |
NCT00112229CT.gov Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients | — | Completed | — | — | — |
NCT00059475CT.gov Peptide Vaccination for Patients at High Risk for Recurrent Melanoma | — | Completed | — | — | — |
NCT00019682CT.gov Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Montanide Isa 51 (this asset) | Nina Bhardwaj | P3 | B · 60 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Ipilimumab | M.D. Anderson Cancer Center | P4 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
| Sargramostim | Mayo Clinic | P3 | BB |
| Pembrolizumab | Biocon Biologics UK PLC | P4 | BB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
+42 more in the Melanoma cohort
Other indications for Montanide Isa 51
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 65 |
| Metastatic Melanoma | — | P2 | BB · 64 |
| Lung Cancer | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Montanide Isa 51 in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/montanide-isa-51-melanoma-45014
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →